32. The method of claim 31, wherein the composition further comprises at least one component selected from the group consisting of: physiologically acceptable carriers and non-specific immune response enhancers.

33. The method of claim 23, wherein the composition further comprises at least one component selected from the group consisting of: physiologically acceptable carriers and non-specific immune response enhancers.

34. The method of claim 25, wherein the composition further comprises at least one component selected from the group consisting of: physiologically acceptable carriers and non-specific immune response enhancers.

35. A method for modulating an immune response in a patient, comprising:

(a) administering to the patient a composition comprising an isolated polypeptide, wherein the polypeptide comprises a sequence selected from the group consisting of sequences having at least 95% identity to SEQ ID NO: 33 and is able to bind to fibroblast growth factor; and

(b) modulating an immune response in the patient.

36. The method of claim 35, wherein the composition further comprises at least one component selected from the group consisting of: physiologically acceptable carriers and non-specific immune response enhancers.

37. A method for enhancing an immune response in a patient, comprising:

(a) administering to the patient a composition comprising an isolated polypeptide, wherein the polypeptide comprises a sequence selected from the group consisting of sequences having at least 95% identity to SEQ ID NO: 33 and is able to bind to fibroblast growth factor; and

(b) enhancing an immune response in the patient.

38. The method of claim 37, wherein the composition further comprises at least one component selected from the group consisting of: physiologically acceptable carriers and non-specific immune response enhancers.--

Amend claims 23 and 25 as follows:

23. (Amended) A method for modulating an immune response in a patient, comprising:

(a) administering to the patient a composition comprising an isolated polypeptide, the polypeptide comprising SEQ ID NO: 33, and

(b) modulating an immune response in the patient.

25. (Amended) A method for modulating an immune response in a patient, comprising:

(a) administering to the patient a composition comprising an isolated polypeptide, the polypeptide comprising an amino acid sequence selected from the group consisting of: sequences having at least 95% identity to SEQ ID NO: 33, wherein the polypeptide has the same functional properties as SEQ ID NO: 33; and

(b) modulating an immune response in the patient.

REMARKS

Favorable reconsideration of the subject patent application is respectfully requested in view of the above amendments and the following remarks. Following the amendments, claims 23, 25 and 29-38 are under consideration in the application, with claims 23, 25, 29, 31, 35 and 37 being in independent format.

The specification has been amended to correct a typographical error and to remove hyperlinks.

Claims 24 and 26 have been cancelled from the application and rewritten as independent claims 29 and 31. Newly added claims 30, 32, 33 and 34 are dependent upon claims 29, 31, 23 and 25, respectively, and are drawn to methods comprising administering a composition, wherein the composition comprises an inventive polypeptide and at least one component selected from the group consisting of physiologically acceptable carriers and non-specific immune response enhancers. Support for newly added claims 30 and 32-34 may be found on page 18, line 24 - page 20, line 15 of the specification as originally filed. Newly added claims 35 and 37 are drawn to methods for modulating and enhancing, respectively, an immune response including administering a composition comprising a polypeptide, the polypeptide comprising a sequence having at least 95% identity to SEQ ID NO: 33 and having the ability to bind to fibroblast growth factor. Newly added claims 36 and 38 are dependent on claims 35 and 37, respectively, and are drawn to such methods wherein the composition further comprises at least one component selected from the group consisting of physiologically acceptable carriers and non-specific